LP
ELOX

LMR Partners’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

LMR Partners’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-361
Closed -$29K – 1279
2021
Q2 		$29K Buy
+361
New +$30.1K ﹤0.01% 1050

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

LMR Partners's ELOX Position: Q3 2021 in Review

LMR Partners sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q3 2021, closing a stake of 361 shares — an estimated $29K sold.

LMR Partners first reported a position in ELOX in Q2 2021 and held it in 1 quarter. The position peaked at $29K in Q2 2021. 40 funds tracked by Wall St. Rank hold ELOX as of Q3 2021.

  • LMR Partners reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • LMR Partners sold 361 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $29K.
  • LMR Partners first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • LMR Partners's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $29K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.